ACA Copay CAP Act of 2025

Bill Number

H.R. 6171

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-11-20: Referred to the House Committee on Energy and Commerce.

Last Updated

2025-12-05T14:21:50Z

AI-Generated Summary

Purpose of the Legislation

The ACA Copay CAP Act of 2025 aims to make prescription drugs more affordable for individuals covered by health insurance plans under the Patient Protection and Affordable Care Act (ACA, commonly known as Obamacare) by setting a yearly limit on out-of-pocket costs (the amount patients pay directly, like copays or deductibles) for these drugs.

Key Provisions

• Annual Out-of-Pocket Limit for Prescription Drugs: Starting with health plan years on or after January 1, 2027, patients cannot be required to pay more than a set amount in cost-sharing for prescription drugs during the year.
• For self-only coverage (individual plans): $2,000 in 2027.
• For family or other coverage: Twice the self-only amount (e.g., $4,000 in 2027).
• Annual Adjustments: The limit increases each year based on the "premium adjustment percentage" (a measure set by the Secretary of Health and Human Services to reflect rising healthcare costs). Increases are rounded down to the nearest $50.
• Application to Plans: This limit applies to all ACA-compliant health plans, including those offered through marketplaces, employers, or government programs like Medicaid expansions.
• Conforming Changes: Once the limit is reached, plans cannot charge additional cost-sharing for prescription drugs for the rest of the year, with exceptions aligned for preventive services (like certain screenings that are already free under the ACA).

Significant Changes to Existing Law

• Adds a new, drug-specific cap to Section 1302(c) of the ACA, which previously set a general out-of-pocket maximum for all medical services but did not single out prescription drugs.
• Updates related sections in the ACA and the Public Health Service Act to ensure the drug cap integrates with existing rules on cost-sharing limits and preventive care exemptions.
• Shifts from no dedicated drug cap to a targeted one, potentially overriding parts of broader out-of-pocket rules for drug expenses starting in 2027.

Potential Impacts

• On Citizens: Reduces financial strain for patients with chronic conditions or high-cost medications, potentially improving access to necessary drugs and preventing medical debt. Low- and middle-income families enrolled in ACA plans may see the most direct benefits.
• On Government Agencies: The Department of Health and Human Services (HHS) will need to calculate and publish annual adjustments to the caps, increasing administrative workload but aligning with its role in overseeing ACA implementation.
• On Health Insurers and Providers: Insurers may face higher costs after patients hit the cap, possibly leading to premium increases or changes in plan designs. Pharmaceutical companies could see shifts in drug utilization patterns.
• No Apparent International Relations Impact: The bill focuses on domestic health policy and does not address foreign trade, imports, or global agreements related to drugs.

Main Stakeholders Affected

• Patients and Consumers: Primary beneficiaries, especially those with ongoing prescription needs (e.g., for diabetes, cancer, or heart disease treatments).
• Health Insurers: Must comply with the new caps, potentially affecting profitability and plan offerings.
• Pharmaceutical Manufacturers: Indirectly impacted through possible increases in drug prescriptions once cost barriers are lowered.
• Healthcare Providers: May see more patients able to afford treatments, but could face negotiations with insurers over coverage.
• Federal Government (HHS and Congress): Responsible for enforcement, adjustments, and monitoring compliance.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens ACA protections by addressing a gap in drug affordability without altering the law's core structure; could face challenges if seen as increasing federal mandates on private insurers, but aligns with Congress's authority to regulate interstate commerce in healthcare.
• Constitutional: No direct conflicts noted, as it builds on existing ACA frameworks upheld by the Supreme Court; promotes equal access to healthcare, a policy goal without infringing on individual rights.
• Political: Advances Democratic priorities on healthcare affordability amid ongoing debates over drug pricing (e.g., linking to Inflation Reduction Act efforts). May spark partisan divides, with supporters viewing it as patient relief and opponents concerned about costs to the insurance market or unintended premium hikes. If passed, it could set a precedent for future targeted caps on other healthcare expenses.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Auchincloss, Jake [D-MA-4]

Recent Actions

• 2025-11-20: Referred to the House Committee on Energy and Commerce.
• 2025-11-20: Introduced in House
• 2025-11-20: Introduced in House

Bill Versions

• ACA Copay Cost and Affordability for Patients Act of 2025 — issued 2025-11-20 — PDF (4 pages)